Evaluation of Rare Antinuclear Antibody Patterns in a Tertiary Hospital in İzmir

Objective: Antinuclear antibody ANA patterns are evaluated as nuclear, cytoplasmic or mitotic on HEp-2 cel l. Although some ANA patterns have been comprehensively studied such as homogenous, speckled or nucleolar staining patterns, rare antinuclear antibody patterns still require further assessment. In this study, the rare pattern was defined as 1% occurring ratio on indirect immunofluorescence assay. Rare ANA patterns were evaluated in a 6-year period retrospectively.Material and methods: The study includes 41921 serum samples that different departments had sent to the tertiary Hospital’s Laboratory of Medical Microbiology for ANA test between January 2010 and December 2015. Serum samples were studied in dilution of 1:100 using HEp20-10/liver biochip Monkey and conjugated with specific antihuman IgG Euroimmun AG, Lubeck, Germany . The fluorescence intensity was evaluated at x400 by immunofluorescence microscope Eurostar III plus . Evaluation was performed as semi-quantitatively from 1+ to 4+. Positive +4 and negative control were used.Results: Of these samples, 9908 23.6% were ANA-IIF-positive. Totally 168 samples were considered as rare autoantibody. Rare patterns were consisted of 49 0.49% midbody, 29 0.29% centriole, 20 0.20% spindle fibers, 21 0.21% anti-golgi, 37 0.37 anti-actin, 3 0.03% rods and rings, and 9 0.09% PCNA proliferating cell nuclear antigen -like. The number of females and males who have rare antibody was 101 and 67, respectively. All of the samples presented a fluorescence of ≥2+. There were 29 patients with systemic autoimmune diseases SAID from the rheumatology department. Another 139 patients were from gastroenterology, endocrinology, neurology and general internal medicine departments.Conclusion: This article shared 6-year experience associated with rare ANA patterns. The significance of our results also emanates from the fact that they document a tertiary hospital’s epidemiological data in Turkey

Keywords:

Antinuclear antibody, rare autoantibody immunofluorescence pattern,

PDF

___

Vermeersch P, Bossuyt X. Prevalence and clinical significance of rare antinuclear antibody patterns. Autoimmun Rev 2013;12:998–1003. [CrossRef]
Sener AG, Afsar I, Demirci M. Evaluation of antinuclear antibodies by indirect immunofluorescence and line immunoassay methods: four years’ data from Turkey. APMIS 2014;122:1167–1170. [CrossRef]
Şener AG, Afşar I. Frequency of dense fine speckled pattern in immunofluorescence screening test. Eur J Rheumatol 2015;2:103– 105. [CrossRef]
Skop AR, Liu H, Yates J 3rd, Meyer BJ, Heald R. Dissection of the mammalian midbody proteome reveals conserved cytokinesis mechanisms. Science 2004;305:61–66. [CrossRef]
Glotzer M. The molecular requirements for cytokinesis. Science 2005;307:1735–1739. [CrossRef]
Fang F, Wang HL, Ye P, et al. Detection of autoantibodies in the serum of primary hepatocarcinoma patients. Hepatobiliary Pancreat Dis Int 2002;1:94–95.
Granito A, Muratori L, Muratori P, et al. Antibodies to filamentous actin (F-actin) in type-1 autoimmune hepatitis. J Clin Pathol 2006;59:280–284. [CrossRef]
Himoto T, Fujita K, Nomura T, et al. Diagnostic Dilemma in the Detection of Antibodies to Filamentous Actin. Clin Lab 2016;62:839– 847.
Schotte H, Willeke P, Schmalhorst J, Schlüter B. Diagnostic Performance of an Anti-Actin Autoantibody Binding Enzyme Immunodot Blot in Autoimmune Hepatitis Type 1. J Clin Lab Anal 2016;30:123–129. [CrossRef]
Couto CA, Bittencourt PL, Porta G, et al. Antismooth muscle and antiactin antibodies are indirect markers of histological and biochemical activity of autoimmune hepatitis. Hepatology 2014;59:592–600. [CrossRef]
Chan EK, Damoiseaux J, Carballo OG, et al. Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014–2015. Front Immunol 2015;6:412. [CrossRef]
Mack GJ, Rees J, Sandblom O, Balczon R, Fritzler MJ, Rattner JB. Autoantibodies to a group of centrosomal proteins in human autoimmune sera reactive with the centrosome. Arthritis Rheum 1998;41:551–558. [CrossRef]
Hamaguchi Y, Matsushita T, Hasegawa M, et al. High incidence of pulmonary arterial hypertension in systemic sclerosis patients with anti-centriole autoantibodies. Mod Rheumatol 2015;25:798–801. [CrossRef]
Terreri T, Niederhoff A, Zabel M, Blum U, Peter HH. Anti-centriole antibodies and high neuron-specific enolase activity in a patient with Raynaud phenomenon, cerebrovascular lesions, and ischemic finger necrosis –a functional relationship? Immun Infekt 1993;21 Suppl 1:22–23.
Rodríguez JL, Gelpi C, Thomson TM, Real FJ, Fernández J. Anti-golgi complex autoantibodies in a patient with Sjögren syndrome and lymphoma. Clin Exp Immunol 1982;49:579–586.
Fritzler MJ, Etherington J, Sokoluk C, Kinsella TD, Valencia DW. Antibodies from patients with autoimmune disease react with a cytoplasmic antigen in the Golgi apparatus. J Immunol 1984;132:2904–2908.
Seelig HP, Schranz P, Schröter H, Wiemann C, Renz M. Macrogolgin –a new 376 kD Golgi complex outer membrane protein as target of antibodies in patients with rheumatic diseases and HIV infections. J Autoimmun 1994;7:67–91.
Hong HS, Chung WH, Hung SI, Chen MJ, Lee SH, Yang LC. Clinical association of anti-golgi autoantibodies and their autoantigens. Scand J Immunol 2004;59:79–87.
Hattori H, Nagata E, Ishihara T, et al. Inflammatory myopathy with anti-Golgi antibody and anti-SS-A/Ro antibody. Intern Med 2007;46:1927–1930.
Mozo L, Simó A, Suárez A, Rodrigo L, Gutiérrez C. Autoantibodies to Golgi proteins in hepatocellular carcinoma: case report and literature review. Eur J Gastroenterol Hepatol 2002;14:771–774.
Bonaci-Nikolic B, Andrejevic S, Bukilica M, Urosevic I, Nikolic M. Autoantibodies to mitotic apparatus: association with other autoantibodies and their clinical significance. J Clin Immunol 2006;26:438–446. [CrossRef]
Chan EK, Damoiseaux J, de Melo Cruvinel W, et al. Report on the second International Consensus on ANA Pattern (ICAP) workshop in Dresden 2015. Lupus 2016;25:797–804. [CrossRef]
Miyachi K, Fritzler MJ, Tan EM. Autoantibody to a nuclear antigen in proliferating cell. J Immunol 1978;121:2228–2234.
Beyne-Rauzy O, Thébault S, Adoue D, Fortenfant F. Anti-PCNA antibodies: prevalence and predictive value. Joint Bone Spine 2005;72:432–435. [CrossRef]
Fredi M, Cavazzana I, Quinzanini M, et al. Rare autoantibodies to cellular antigens in systemic lupus erythematosus. Lupus 2014;23:672–677. [CrossRef]
Vermeersch P, De Beeck KO, Lauwerys BR, et al. Antinuclear antibodies directed against proliferating cell nuclear antigen are not specifically associated with systemic lupus erythematosus. Ann Rheum Dis 2009;68:1791–1793. [CrossRef]
Stinton LM, Myers RP, Coffin CS, Fritzler MJ. Clinical associations and potential novel antigenic targets of autoantibodies directed against rods and rings in chronic hepatitis C infection. BMC Gastroenterol 2013;13:50. [CrossRef]
Carcamo W, Ceribelli A, Chan J, et al. Autoantibodies to a novel cytoplasmic Rod/Ring structure target CTP/GTP synthetic pathway in HCV infection after Interferon/Ribavirin therapy. Arthritis Rheum 2010;62(Suppl 10):1639.
Shaikh Y, Krantz A, El-Farra Y. Anti-rods and rings autoantibodies can occur in the hepatitis C-naïve population. J Prev Med Hyg 2013;54:175–180.